Additional file 1 of NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

Additional file 1. Supplementary methods. Supplementary Figure 1. Clinicopathological features and DEG in NK cell rich virus NK cell desert HER2+ tumors. Supplementary Figure 2. Contribution of IFN-ɣ, TNF-α and type I IFNs to the production of CXCL9 and CXCL10 upon NK cell-medicated ADCC against SKBR3 cells. Supplementary Table 1. Clinicopathological features of tumor specimens included inflow cytometry analysis of immune in filtrates. Supplementary Figure 3. Identification of TI-NK cell and T cell subsets in treatment naïve breast carcinomas. Supplementary Figure 4. Influence of tumor subtype in the composition of immune infiltrates. Supplementary Figure 5. Gating strategy and differential expressed genes of circulating and tumor-infiltrating NK cell subsets. Supplementary Table 2. Clinipathological features of patients included in longitudinal chemokine studies. Supplementary Figure 6. Systemic CCL5, CXCL9 and CXCL0 in HER2+ breast cancer patients.